Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mersana Therapeutics excels in 2022, poised for oncology innovation

Mersana Therapeutics demonstrated strong performance, financial stability, and clinical progress in 2022, positioning themselves as a key player in oncology drug development.
While facing challenges in regulatory considerations and competitive dynamics, the company's strategic collaborations and pipeline advancements offer promising opportunities for future growth.
Investors should monitor Mersana's upcoming milestones, including data reporting and trial progress, as indicators of their potential for continued success and innovation.

Mersana Therapeutics progresses in Q1 with strong financials and clinical trials

Mersana Therapeutics is on track for a pivotal year with strong financials, progress in clinical trials, and plans for potential BLA submission. Challenges include diagnostic testing bottlenecks and patient pre-treatment impact on response rates. Opportunities exist in data presentations, partnerships, and subgroup analysis for improved outcomes.

Mersana Therapeutics reports improved Q3 performance and strategic partnerships

Mersana Therapeutics demonstrated improved financial performance, strong partnerships, and a focus on innovative ADC candidates. While facing challenges with clinical setbacks, the company's strategic restructuring and promising pipeline indicate opportunities for growth and success in the ADC market.

Mersana Therapeutics shows financial improvement and pipeline promise in Q1

Mersana Therapeutics demonstrated improved financial performance in Q1 2024 with reduced expenses and a lower net loss compared to the previous year.
Strengths in ADC platform advancements and promising lead candidates position Mersana well for future growth and innovation.
Challenges in clarifying key strategies and managing expenses underscore areas for improvement, while opportunities in expansion and partnerships offer avenues for advancement.

Mersana Therapeutics reports strong Q2 progress amidst financial challenges

Mersana Therapeutics demonstrated strong progress in Q2 2024 with promising clinical data for XMT-1660 and XMT-2056 ADC candidates, despite reporting a net loss.
The company's focus on optimizing dosing schedules, exploring biomarkers, and addressing resistance mechanisms underscores a commitment to advancing its pipeline.
Analysts' interest in patient responses, dosing schedules, and expansion plans highlights the market's anticipation of Mersana's future growth and innovation in the ADC space.

Mersana Therapeutics progresses ADC trials, strengthens finances, and faces resistance

Mersana Therapeutics demonstrated strong performance in advancing ADC candidates and managing finances effectively in Q3 2024.
While facing challenges such as resistance to existing ADCs, the company is well-positioned to capitalize on opportunities in innovative therapies.
Strategic planning for clinical trial expansions and business development will be crucial for Mersana's continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company's Phase 1 clinical trial of XMT-2056. XMT-2056 is a systemically administered Immunosynthen STING-agonist ADC that is designed to target a novel human epidermal growth factor receptor 2 (HER2) epitope and locally activate STING signaling in both tumor-resident immune cells and in tumor cells, providing the potential to treat patients with HER2-high or -low tumors as monotherapy and in combination with standard-of-care agents.

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the appointment of Martin Huber, M.D., current member of the Board of Directors, as President and CEO, effective September 11, 2023. Dr. Huber and Ms. Protopapas will both remain members of Mersana's Board of Directors following the transition.

Mersana Therapeutics Announces Changes in Leadership

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)

Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary endpoint. UpRi is an ADC targeting the sodium-dependent phosphate transport protein NaPi2b and was developed utilizing the company's Dolaflexin platform.

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

NEW YORK , June 27, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Mersana Therapeutics, Inc. (NASDAQ: MRSN). To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/mersana-class-action-loss-submission-form/?wire=4 Further details on the investigation: On June 15, 2023, Mersana issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.

MRSN FRAUD ALERT: Jakubowitz Law is Investigating Mersana Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws

NEW YORK , June 27, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) violated federal securities laws. CURRENT INVESTIGATION DETAILS:On June 15, 2023, Mersana issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.

MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

NEW YORK , June 26, 2023 /PRNewswire/ -- Attention Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Mersana and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: On June 15, 2023, Mersana issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.

MRSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws

NEW YORK , June 22, 2023 /PRNewswire/ -- Attention Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Mersana and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: On June 15, 2023, Mersana issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.

MSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws

NEW YORK , June 21, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) concerning possible violations of federal securities laws. On June 15, 2023, Mersana issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.

MRSN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.

Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold

Mersana Therapeutics (NASDAQ:MRSN) stock plummeted more than 60% on Thursday after the clinical-stage biopharmaceutical company announced that the Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in its ongoing clinical trials evaluating its therapeutic UpRi in platinum-sensitive ovarian cancer, UP-NEXT and UPGRADE-A.  The partial clinical hold comes after Mersana submitted aggregate safety reports of all patients dosed with UpRi, approximately 560 patients, evaluating bleeding events.

Mersana Therapeutics shares tank as FDA puts ovarian cancer drug trials on partial hold

Mersana Therapeutics Inc said on Thursday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its ovarian cancer drug studies and paused patient enrollment, citing safety concerns.

US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold

Mersana Therapeutics Inc.'s stock MRSN cratered 73% premarket Thursday, after the company announced that the U.S. Food and Drug Administration had placed a partial clinical hold on two trials of a treatment for ovarian cancer after five participants died. The agency has directed to company to pause new patient enrollment in the trials dubbed Up-Next and Upgrade-A, which are evaluating UpRi in platinum-sensitive ovarian cancer.

Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events

CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

Aeva Technologies Inc

iQIYI

Lovesac Company

OmniAb Inc

Plug Power

Rush Street Interactive

In order for a stock to provide 200% returns it needs to at least triple in price. That's the kind of shares we'll be discussing below.

7 Stocks to Buy for 200% Returns This Year

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Jason Fredette – Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas – President and Chief Executive Officer Arvin Yang – Chief Medical Officer Brian DeSchuytner – Chief Financial Officer Conference Call Participants Brian Cheng – J.P. Morgan Jonathan Chang – SVB Securities Colleen Kusy – Baird Kaveri Pohlman – BTIG Ashiq Mubarack – Citi Boris Peaker – Cowen Asthika Goonewardene – Truist David Nierengarten – Wedbush Securities Operator Good morning, and welcome to Mersana Therapeutics First Quarter 2023 Conference Call and Webcast.

Mersana Therapeutics, Inc. (MRSN) Q1 2023 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.59 per share a year ago.

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the first quarter ended March 31, 2023.

Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 12:20 p.m. Eastern Time.

Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the acceptance of multiple abstracts for poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place in Chicago from June 2-6, 2023.

News for Mersana Therapeutics Stock (MRSN)